Dianhydrogalactitol - DelMar Pharmaceuticals

Drug Profile

Dianhydrogalactitol - DelMar Pharmaceuticals

Alternative Names: DAG for Injection; Dianhydrodulcitol; Diepoxydulcitol; Diepoxygalactitol; NSC-1323313; VAL-083

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DelMar Pharmaceuticals
  • Developer DelMar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Ethylene glycols; Small molecules
  • Mechanism of Action Alkylating agents; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Ovarian cancer; Medulloblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic myeloid leukaemia; Lung cancer

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Lung cancer
  • Phase III Glioblastoma
  • Clinical Phase Unknown Haematological malignancies; Solid tumours
  • Preclinical Medulloblastoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 04 Oct 2017 DelMar plans a phase II and phase III trial for Ovarian cancer
  • 20 Sep 2017 The United States Patent and Trademark Office issues new patent to DelMar Pharmaceuticals for dianhydrogalactitol in USA
  • 18 Sep 2017 DelMar Pharmaceuticals plans to initiate the REPROVe phase I/II trial for Ovarian cancer in December 2017 (Second-line therapy or greater) in USA (NCT03281681)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top